newsfilter
← Latest News
PR Newswire·

Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020

  • Eli Lilly broke ground on a $3.5 billion injectable medicine manufacturing facility in Lehigh Valley, Pennsylvania.
  • The site will produce next-generation obesity treatments, including the investigational drug retatrutide.
  • Construction is expected to create 2,000 jobs, with the operational facility targeting 850 high-wage positions.
  • The facility is scheduled to become operational by 2031.
  • Lilly plans to invest up to $1 million over five years to support a community initiative focused on nutrition, health resources, \& quality-of-life programs in Upper Macungie Township.
  • The site will utilize advanced technologies, including machine learning, AI, \& digital automation to ensure quality control.
  • The facility targets Leadership in Energy and Environmental Design (LEED) Gold certification for sustainable performance.
  • This project is part of a larger $50 billion U.S. manufacturing expansion announced since 2020.
  • Retatrutide is an investigational triple hormone receptor agonist currently undergoing Phase 3 clinical trials for obesity, type 2 diabetes, \& other conditions.
Company
Eli Lilly and Company
Keywords
Eli Lilly and Company